GSP Crop Science Q3 & 9M FY26 Investor Presentation Released; Revenue Up 14%
GSP Crop Science released its Q3 & 9M FY26 investor presentation on April 17, 2026. Consolidated revenue rose 14% to ₹11,146 million, with EBITDA up 32% to ₹1,538 million and PAT up 26% to ₹751 million. Standalone revenue increased 9% to ₹11,766 million, EBITDA by 23% to ₹1,296 million, and PAT by 28% to ₹682 million.
The investor presentation provides detailed financial results and business highlights, which are crucial for investors to assess the company's performance and future prospects. The growth figures are substantial enough to warrant medium impact.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT for both consolidated and standalone financial performances, indicating a positive business trajectory.
GSP Crop Science Limited has released its Investor Presentation for the Third quarter and nine months ended December 31, 2025. The presentation was made available on April 17, 2026.
The company highlighted its business overview, emphasizing its extensive product portfolio of insecticides, herbicides, fungicides, and plant growth regulators, catering to both domestic and international markets. GSP Crop Science operates a B2B and B2C business for technical and formulation products domestically, with 219 formulation and 63 technical registrations. Internationally, the company operates in 37 countries with 176 formulation and 60 technical product registrations.
Key strengths include robust in-house R&D capabilities with a strong focus on innovation and product development, evidenced by 102 granted patents and 108 patent applications under process. The company also holds exclusive process patents for technical products and is among the top Indian applicants for Patent Cooperation Treaty filings. GSP Crop Science has a diversified product portfolio and operates five manufacturing facilities across India, holding ISO certifications for quality and safety.
In terms of financial performance for the 9 months ended December 31, 2025 (9M FY26), consolidated revenue increased by 14% to ₹11,146 million (from ₹9,794 million in 9M FY25), primarily driven by growth in the domestic B2C segment due to new product sales and increased sales of key brands like PCT-410, Torch, Aurthor, and Runout. Consolidated EBITDA saw a significant increase of 32% to ₹1,538 million (from ₹1,168 million in 9M FY25), with EBITDA margins improving to 13.80% from 11.92%. Consolidated Profit After Tax (PAT) rose by 26% to ₹751 million (from ₹596 million in 9M FY25), with PAT margins increasing to 6.74% from 6.09%.
On a standalone basis, revenue for 9M FY26 grew by 9% to ₹11,766 million (from ₹10,799 million in 9M FY25), also attributed to the domestic B2C segment. Standalone EBITDA increased by 23% to ₹1,296 million (from ₹1,058 million in 9M FY25), with margins improving to 11.01% from 9.79%. Standalone PAT grew by 28% to ₹682 million (from ₹533 million in 9M FY25), with margins at 5.80%.
What to do with a filing like this
GSP Crop Science Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by GSP Crop Science Limited. Read the original for the full detail.